{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(12)"],"submitter":["Zhao Z"],"pubmed_abstract":["<h4>Objective</h4>This study aimed to investigate the cost-effectiveness of adding Chinese-developed anti-PD-1 antibody camrelizumab to first-line platinum-doublet chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma (L/M NPC) from the perspective of Chinese healthcare system.<h4>Design</h4>A Markov model consisting of four health states, progression-free survival, first progression survival, second progression survival and death, was built to simulate 3-week patient transitions over a 20-year horizon. A direct comparison between first-line camrelizumab in combination with gemcitabine plus cisplatin and gemcitabine plus cisplatin was performed by calculating transition probabilities from the CAPTAIN-1st trial. Costs and utilities were collected from the local publ"],"journal":["BMJ open"],"pagination":["e071832"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10748990"],"repository":["biostudies-literature"],"pubmed_title":["Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China."],"pmcid":["PMC10748990"],"pubmed_authors":["Liu Q","Guo R","Zhao Z","Chen T","Zhou Z"],"additional_accession":[]},"is_claimable":false,"name":"Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China.","description":"<h4>Objective</h4>This study aimed to investigate the cost-effectiveness of adding Chinese-developed anti-PD-1 antibody camrelizumab to first-line platinum-doublet chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma (L/M NPC) from the perspective of Chinese healthcare system.<h4>Design</h4>A Markov model consisting of four health states, progression-free survival, first progression survival, second progression survival and death, was built to simulate 3-week patient transitions over a 20-year horizon. A direct comparison between first-line camrelizumab in combination with gemcitabine plus cisplatin and gemcitabine plus cisplatin was performed by calculating transition probabilities from the CAPTAIN-1st trial. Costs and utilities were collected from the local publ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Dec","modification":"2025-04-04T12:19:03.851Z","creation":"2025-04-04T12:19:03.851Z"},"accession":"S-EPMC10748990","cross_references":{"pubmed":["38110377"],"doi":["10.1136/bmjopen-2023-071832"]}}